SCHEMBL1784924

SCHEMBL1784924

CCOC(=O)CCNC(=O)OC(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 2/20 0.51
TDP1 Q9NUW8 1/20 0.50
GAA P10253 4/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
ALDH1A1 P00352 3/20 0.46
TSHR P16473 2/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HTT P42858 1/20 0.46
CA12 O43570 2/20 0.45
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
CA9 Q16790 2/20 0.45
MAPT P10636 2/20 0.44
HPGD P15428 2/20 0.44
KDM4E B2RXH2 1/20 0.44
GLA P06280 1/20 0.44
HIF1A Q16665 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15728746 0.94 CTSK (0.50) CTSKTDP1GAAMEN1KMT2A
SCHEMBL19560876 0.90 TDP1 (0.45) CTSKTDP1GAAMEN1KMT2A
SCHEMBL572949 0.90 TDP1 (0.56) CTSKTDP1GAAMEN1KMT2A
SCHEMBL4578241 0.89 MEN1 (0.47) CTSKTDP1GAAMEN1KMT2A
SCHEMBL25095054 0.88 TDP1 (0.58) CTSKTDP1GAAMEN1KMT2A
SCHEMBL156233 0.88 TDP1 (0.46) CTSKTDP1GAAMEN1KMT2A
SCHEMBL9555151 0.88 GAA (0.53) CTSKTDP1GAAMEN1KMT2A
SCHEMBL23782441 0.88 MAOA (0.55) CTSKTDP1GAAMEN1KMT2A
SCHEMBL6136335 0.88 MAOA (0.51) CTSKTDP1GAAMEN1KMT2A
SCHEMBL27238869 0.87 CTSK (0.46) CTSKTDP1GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116874642-A Metal chelate chromatography medium and preparation method thereof 百林科(兰州)新材料有限公司 2023-10-13 CN claimed
US-20250270197-A1 RIBOCIL C ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2025-08-28 US disclosed
US-12180198-B2 Ribocil C antibiotics effective for Gram-negative pathogens THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2024-12-31 US disclosed
US-20240190872-A1 FABI INHIBITORS FOR GRAM-NEGATIVE PATHOGENS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2024-06-13 US disclosed
US-20240116911-A1 RIBOCIL C ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2024-04-11 US disclosed
CN-116874642-A Metal chelate chromatography medium and preparation method thereof 百林科(兰州)新材料有限公司 2023-10-13 CN disclosed
EP-4257131-A2 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS Forma Therapeutics, Inc. (US) 2023-10-11 EP disclosed
WO-2023134698-A1 PYRIDAZINE-1(6H)-6-OXO COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 深圳信立泰药业股份有限公司 2023-07-20 WO disclosed
US-11691967-B2 Antibiotics effective for gram-negative pathogens THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2023-07-04 US disclosed
US-11691967-B2 Antibiotics effective for gram-negative pathogens THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2023-07-04 US disclosed
US-20070238746-A1 THIAZOLYL-DIHYDRO-CHINAZOLINE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-11 US disclosed
US-20070238746-A1 THIAZOLYL-DIHYDRO-CHINAZOLINE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-11 US disclosed
US-20070238746-A1 THIAZOLYL-DIHYDRO-CHINAZOLINE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-11 US disclosed
US-20070032487-A1 Inhibitors of phosphatidylinositol 3-kinase NOVARTIS AG (CH) 2007-02-08 US disclosed
EP-1689391-A2 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES Novartis AG (CH) 2006-08-16 EP disclosed
US-6977262-B2 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2005-12-20 US disclosed
EP-1537106-A1 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS Mitsubishi Pharma Corporation (JP) 2005-06-08 EP disclosed
WO-2005021519-A2 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES NOVARTIS AG (CH) 2005-03-10 WO disclosed
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-03-18 US disclosed
WO-2004014910-A1 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS MITSUBISHI PHARMA CORPORATION (JP) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032487-A1 Inhibitors of phosphatidylinositol 3-kinase PIK3CA, PIP4K2C, PIP4K2B CTSK 1466/4885TDP1 1744/4885GAA 1431/4885
US-11691967-B2 Antibiotics effective for gram-negative pathogens PGLS, MGAM, GMDS CTSK 286/4885TDP1 4238/4885GAA 70/4885
US-20070238746-A1 THIAZOLYL-DIHYDRO-CHINAZOLINE CYP3A7, UGT2B7, UGT1A7 CTSK 1759/4885TDP1 1550/4885GAA 1732/4885
US-20240116911-A1 RIBOCIL C ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENS RPSA, RPS5, RPS2 CTSK 1291/4885TDP1 3533/4885GAA 572/4885
US-20250270197-A1 RIBOCIL C ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENS RPSA, RPS5, RPS2 CTSK 1291/4885TDP1 3533/4885GAA 572/4885
US-12180198-B2 Ribocil C antibiotics effective for Gram-negative pathogens RPSA, RPS5, RPS2 CTSK 1291/4885TDP1 3533/4885GAA 572/4885
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof GSK3B, GSK3A, PYGB CTSK 2772/4885TDP1 550/4885GAA 229/4885
US-20240190872-A1 FABI INHIBITORS FOR GRAM-NEGATIVE PATHOGENS DBI, MGAM, MGAM2 CTSK 96/4885TDP1 4652/4885GAA 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.